The peripheral nervous system is responsible for transmitting signals between the brain, spinal cord, and muscles. These nerves control voluntary movement, reflexes, and muscle coordination. In dogs affected by LPN2, a genetic mutation disrupts normal nerve cell function, leading to degeneration of peripheral nerves over time. This results in progressive loss of communication between the nervous system and muscles, causing weakness and impaired motor control.
Clinical signs of LPN2 typically appear in young to middle-aged dogs, although the severity and age of onset can vary. Early symptoms may include exercise intolerance, reduced stamina, and mild weakness in the hind limbs. As the disease progresses, affected dogs may develop more obvious neurological signs such as unsteady gait (ataxia), difficulty rising, and muscle wasting (atrophy), particularly in the hindquarters.
Over time, LPN2 can lead to more severe motor dysfunction. Dogs may show a wide-based stance, dragging of the hind limbs, and difficulty maintaining balance during movement. Reflexes may become reduced or absent, and muscle mass may decrease due to lack of nerve stimulation. In advanced cases, mobility may be significantly compromised, impacting quality of life.
The LPN2 DNA Health Test is designed to detect the specific genetic mutation associated with Leonberger Polyneuropathy. The test is simple, safe, and non-invasive, typically performed using a cheek swab or blood sample. The collected DNA is analyzed in a specialized laboratory to determine whether the dog carries zero, one, or two copies of the mutation. Since genetic information does not change over time, testing can be performed at any age, including in puppies before symptoms develop.
Results are generally reported in three categories:
- Clear (Normal): The dog does not carry the LPN2 mutation and is not expected to develop or pass on the disease.
- Carrier: The dog carries one copy of the mutation but typically does not show clinical signs. However, it can pass the mutation to future generations.
- Affected/At Risk: The dog carries two copies of the mutation and is expected to develop progressive neurological signs associated with LPN2.
Genetic testing for LPN2 is extremely valuable for breeders, veterinarians, and dog owners. Breeders can use test results to make informed breeding decisions that reduce the prevalence of polyneuropathy while maintaining healthy genetic diversity within the breed population. Avoiding carrier-to-carrier matings is essential to prevent affected puppies.
For dog owners, knowing a dog’s genetic status allows for early recognition and management of neurological decline. While there is currently no cure for LPN2, supportive care such as physiotherapy, controlled exercise, mobility assistance, and regular veterinary monitoring can help improve comfort and quality of life in affected dogs.
The Leonberger Polyneuropathy (LPN2) Health Test is a reliable genetic screening tool that supports responsible breeding practices, promotes canine neurological health, and helps reduce the impact of this inherited peripheral nerve disorder in future generations.
